Abstract：Objective To compare the difference in the effects of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) on immunological responses in children with asthma. Methods A total of 86 children with asthma caused by dust mites were enrolled and divided into a SLIT group (n=29), a SCIT group (n=13), a group receiving complete SCIT course (complete SCIT group; n=14), and a group receiving conventional medication (control group, n=30). Peripheral blood mononuclear cells were isolated and stimulated with house dust mite extract for 48 hours in vitro, and the percentage of regulatory T cells (Treg%) in CD4+ T cells was measured by flow cytometry. Analysis of variance with repeated measures was applied to compare the changes in humoral immunological indices and therapeutic effects in the SCIT and SLIT groups before treatment and after 6 and 12 months of treatment. Results Before antigenic stimulation, Treg% in CD4+ T cells in the SCIT group was significantly higher than that in the SLIT and control groups; after antigenic stimulation was given, Treg% in the four groups decreased significantly. After 6 and 12 months of immunotherapy, the SCIT group had significant changes in serum sIgE and sIgG4 levels, while the SLIT group only showed a significant change in serum sIgE level. Conclusions Temporal difference exists in different immunotherapies to cause immunological responses in children with asthma, and immunological responses induced by SCIT may occur earlier.
MIAO Qing,WANG Jing,XU Wei et al. A comparision of the effects of subcutaneous and sublingual immunotherapy on immunological responses in children with asthma[J]. CJCP, 2015, 17(11): 1210-1216.
Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization American academy of allergy, asthma and immunology[J]. Ann Allergy Asthma Immunol, 1998, 81(5 pt 1): 401-405.
[6]
Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience[J]. Curr Opin Otolaryngol Head Neck Surg, 2014, 22(3): 208-210.
[7]
Steinke JW, Lawrence MG. T-cell biology in immunotherapy[J]. Ann Allergy Asthma Immunol, 2014, 112(3): 195-199.
Brozek JL, Bousquet J, Baena-Caqnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3): 466-476.
[10]
Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma[J]. Allergy, 2011, 66(2): 178-185.
Canoniea GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunothempy for respiratory allergy. A statement of a World Allergy Organization (WAO) task force[J]. Allergy, 2007, 62(3): 317-324.
Jutel M, Akdis M, Blaser K, et al. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more[J]. Allergy, 2006, 61(7): 796-807.
[16]
Akdis CA, Blaser K, Akdis M. Mechanisms of allergen-specific immunotherapy[J]. Chem Immunol Allergy, 2006, 91: 195-203.
[17]
Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy[J]. Curr Allergy Asthma Rep, 2014, 14(11): 473.
[18]
Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases[J]. Curr Opin Pharmacol, 2014, 17: 30-37.
[19]
Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials [J]. Am J Respir Crit Care Med, 1995, 151(4): 969-974.
[20]
Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review [J]. Allergy, 1999, 54(10): 1022-1041.
[21]
Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma[J]. Cochrane Database Syst Rev, 2000, (2): CD001186.
[22]
Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma[J]. Cochrane Database Syst Rev, 2003, (4): CD001186.
[23]
Calamita Z, Saconato H, Pelá AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method [J]. Allergy, 2006, 61(10): 1162-1172.
[24]
Antúnez C, Mayorga C, Corzo JL, et al. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration[J]. Pediatr Allergy Immunol, 2008, 19(3): 210-218.
[25]
Durham SR, Walker SM, Varga EM, et al. Long term clinical efficacy of grass-pollen immunotherapy[J]. N Engl J Med, 1999, 341(7): 468-475.
[26]
Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper[J]. J Allergy Clin Immunol, 1998, 102(4 Pt 1): 558-562.
